Modality
ADC
MOA
CD3xCD20
Target
CD3
Pathway
Proteasome
FSGSMSHuntington's
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
May 2017
→ Sep 2031
Phase 2Current
NCT03402452
1,421 pts·MS
2017-05→2031-09·Completed
1,421 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-175.5y awayPh2 Data· MS
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Complet…
Catalysts
Ph2 Data
2031-09-17 · 5.5y away
MS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03402452 | Phase 2 | MS | Completed | 1421 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 |